Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026)
Erasca (ERAS) reported Total Non-Current Liabilities of $67.4 million for Q1 2026, down 5.77% on a YoY basis from $71.5 million in Q1 2025, and down 4.56% quarter-over-quarter from $70.6 million in Q4 2025.
Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Erasca has reported Total Non-Current Liabilities for 7 years, with the latest figure at $67.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 5.77% year-over-year to $67.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.4 million (down 5.77% YoY), and the FY2025 full-year result was $70.6 million, down 10.27% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $67.4 million, down from $70.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $102.5 million in Q4 2022, with the low at $67.4 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $77.5 million across 5 years, with a median of $77.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 129.12% — and 2023, when it decreased 23.85%.
- Erasca's Total Non-Current Liabilities stood at $102.5 million in 2022, then fell by 23.85% to $78.0 million in 2023, then increased by 0.79% to $78.7 million in 2024, then dropped by 10.27% to $70.6 million in 2025, then retreated by 4.56% to $67.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $67.4 million (Q1 2026), $70.6 million (Q4 2025), and $72.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 67.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.37 Mn |
| Dec 31, 2025 | 70.58 Mn |
| Sep 30, 2025 | 72.12 Mn |
| Jun 30, 2025 | 72.87 Mn |
| Mar 31, 2025 | 71.49 Mn |
| Dec 31, 2024 | 78.67 Mn |
| Sep 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 74.58 Mn |
| Mar 31, 2024 | 81.05 Mn |
| Dec 31, 2023 | 78.05 Mn |
| Sep 30, 2023 | 79.67 Mn |
| Jun 30, 2023 | 77.26 Mn |
| Mar 31, 2023 | 80.46 Mn |
| Dec 31, 2022 | 102.48 Mn |
| Dec 31, 2021 | 44.73 Mn |
| Dec 31, 2020 | 15.79 Mn |